secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001703057-26-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera FY2025 revenue $75.1M, net loss $146.4M; liquidity ~$700M
-------------------------------------------------------------------

- Revenue $75.1M vs $28.8M YoY; net loss $146.4M vs $162.9M; EPS $(0.49) vs $(0.55).
- Available liquidity ~$700M ($561M cash + $135M non-dilutive govt funding).
- Advanced ABCL635 into Phase 2, ABCL575 in Phase 1; two candidates into IND/CTA-enabling.
- Cumulative partner programs 104 (+8), molecules in clinic 19 (+3).
- Appointed Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000010/0001703057-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000010/abcl-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer